Almirall · ISIN: ES0157097017

Almirall’s Nine-Month 2024 Results: Almirall Reports Strong Performance at Q3 2024 - Driven by Successful Commercial Execution of the Dermatology Portfolio, Fuelled by Biologics Growth

Almirall, S.A. (ALM), a global biopharmaceutical company based in Barcelona, today announced its year to date financial results at the third quarter of 2024. Almirall continued to deliver strong sales growth in the first nine months of 2024 which were driven by the dermatology business, and especially the biologics portfolio in Europe. Net Sales i...

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

This news feed is a compilation of company-relevant news from the most popular and widest-reaching newswire services. The feed is updated several times. For market-related publications, we recommend the X-Billboard, the Daily News Digest or our Premium Information Service.
Most recent update: 11.11.2024 | 08:12
11 November 2024 08:12AM
Almirall’s Nine-Month 2024 Results: Almirall Reports Strong Performance at Q3 2024 - Driven by Successful Commercial Execution of the Dermatology Portfolio, Fuelled by Biologics Growth
Almirall, S.A. (ALM), a global biopharmaceutical company based in Barcelona, today announced its year to date financial results at the third quarter of 2024. Almirall continued to deliver strong sales growth in the first nine months of 2024 which were driven by the dermatology business, and especially the biologics portfolio in Europe. Net Sales i...
© BusinessWire
15 October 2024 08:30AM
Almirall Announces Completion of Decentralized Regulatory Approval Procedure for Efinaconazole in Europe
Almirall, S.A. (ALM), a global pharmaceutical company dedicated to medical dermatology announced today the successful completion of the decentralized regulatory procedure in Europe for efinaconazole, a triazole antifungal compound indicated for the treatment of fungal infection of the nail, known as onychomycosis, under the trade name of Jublia®....
© BusinessWire
25 September 2024 12:45PM
New Data Show Almirall´s EBGLYSS® (Lebrikizumab) Provided Sustained Disease Control for up to Three Years in More Than 80% of Adults and Adolescents With Moderate-to-severe Atopic Dermatitis
More than 80 percent of adults and adolescents with moderate-to-severe atopic dermatitis who responded to lebrikizumab treatment at Week 16 in the ADvocate 1 and 2 monotherapy trials and continued treatment for up to three years experienced sustained skin clearance with monthly maintenance dosing. Almirall S.A. (BME: ALM) announced these new long-...
© BusinessWire
23 September 2024 12:09PM
Almirall to Present New Data on Biologics for Psoriasis and Atopic Dermatitis and Celebrates 80 Years of Innovation at the EADV Congress
Almirall, S.A. (ALM), a global pharmaceutical company dedicated to medical dermatology, today announced its participation in the 33rd Congress of the European Academy of Dermatology and Venereology (EADV), taking place in Amsterdam from September 25 to 28, 2024. This year, Almirall marks its 80th anniversary, celebrating eight decades of innovatio...
© BusinessWire

The information service offers company-relevant news from leading newswire services in a compact form for a quick overview. When the detailed view is called up, further information can be accessed if required. The navigation elements in previewer mode allow you to quickly switch to the most frequently visited tool sections. From there, you can access further areas that can be used for your own research and analysis. Tip: The information platform now includes more than 50 mini-apps developed in-house.

AI First: Feel free to test the AI integration that will quickly put you on a par with financial journalists and research houses

Further information

The information presented in this section is secondary publications. The content corresponds to the source information. You can find information on the author of the news item in the detailed information of a publication. News relating to listed companies may have been created due to regulatory publication obligations, due to regular public relations work for PR or marketing reasons or by third parties against the background of investor information.

The combination of information and graphic elements contributes significantly to visual orientation and navigation through complex issues. This makes it easier to grasp, contextualize and process key content. Images, logos and other or comparable graphic and textual elements used on the information portal are used for visual navigation, are part of the original message or have illustrative purposes. All rights to these elements are held by the respective owners of the trademark or image rights. They are used without intent to infringe copyright or intellectual property rights. Image material provided via the distribution networks is treated as part of the original message and processed accordingly.

If you believe that copyright or intellectual property rights have been infringed by the presentation, please contact us immediately to clarify your concerns.